---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001353"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T12:06:36.335580+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Pelthos Therapeutics completes merger, launches ZELSUVMI, hires 50 sales managers

## Summary
- Completed merger with Channel Therapeutics and closed $50.1M private placement on July 1, 2025.
- Launched ZELSUVMI (berdazimer) on July 10, 2025, first at-home FDA-approved treatment for molluscum contagiosum.
- Built commercial team of 90+ employees including 50 territory sales managers; early orders and prescriptions meeting/exceeding expectations.
- In advanced discussions to acquire a second FDA-approved pediatric infectious disease product.
- Public float ~600k shares; market cap ~$55M (~$165M fully diluted); lockup on Series A Preferred through Dec 31, 2025.

## SEC filing metadata
- accession: 0001753926-25-001353
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001353/0001753926-25-001353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001353/g084926_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001353
- JSON: https://secwatch.observer/filing/0001753926-25-001353.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.